Anastrozole vs Rosuvastatin
FDA Approved vs FDA Approved
avoid Mechanism-based · 75% Both Anastrozole and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anastrozole Rosuvastatin
Weight 293.37 Da 481.54 Da
Half-life ~40-50 hours ~19 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) Synthetic statin (C22H28FN3O6S-Ca)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Rosuvastatin
01 Most potent statin available, with LDL reductions of 45-63% depending on dose
02 Long half-life (19 hours) allows flexible once-daily dosing at any time of day
03 Effective at counteracting AAS-induced lipid disturbances, particularly elevated LDL
04 Significant reduction in high-sensitivity CRP (30-50%), indicating anti-inflammatory benefit
05 Hydrophilic structure provides hepatic selectivity with potentially fewer muscle side effects
06 Raises HDL cholesterol by 8-14%, partially offsetting AAS-mediated HDL suppression
07 Proven cardiovascular event and mortality reduction in large-scale clinical trials
08 Reduces triglycerides by 10-35%, beneficial during bulking phases or when using compounds that elevate TG
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Rosuvastatin
Muscle pain and myalgia (5-10% of users) -- the most frequently reported complaint, ranging from mild soreness to significant discomfort
Headache
Nausea and abdominal discomfort
Weakness or fatigue
Constipation or diarrhea
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to rosuvastatin or any excipients
Pregnancy and breastfeeding (Category X -- statins are teratogenic)
Concomitant use with cyclosporine (at all doses of rosuvastatin)
Severe renal impairment (eGFR <30 mL/min) for doses above 10 mg
Research Evidence
Anastrozole Rosuvastatin
Status FDA Approved FDA Approved
References 5 studies 4 studies
Latest — 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.